Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Open Posted
- Opportunity number
- PAR-24-293
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.867 Vision Research
- 93.279 Drug Use and Addiction Research Programs
- 93.113 Environmental Health
- 93.242 Mental Health Research Grants
- 93.213 Research and Training in Complementary and Integrative Health
- 93.866 Aging Research
- 93.121 Oral Diseases and Disorders Research
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- 93.273 Alcohol Research Programs
- Funding instrument
- Cooperative Agreement
- Categories
-
- Environment
- Education
- Health
- Eligible applicants
-
- Special District Governments
- Higher Education Inst. (Public)
- Higher Education Inst. (Private)
- County Governments
- Public or Indian Housing Auth.
- Independent School Districts
- Other
- City/Township Governments
- Non-501(c)(3) Nonprofits
- Tribal Organizations (Not Federally Recognized)
- Small Businesses
- State Governments
- For Profit Organizations
- Tribal Governments (Federally Recognized)
- 501(c)(3) Nonprofits
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health seeks applications for the Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System under cooperative agreement authority (UG3/UH3), with an application due date of August 18, 2027. The program supports preclinical discovery and development of potential therapeutic biologic products, including large biologic macromolecules (proteins, antibodies, peptides), gene-based therapies (oligonucleotide- and viral-based), cell therapies, and emerging therapies (microbial and microbiome) for nervous system and neuromuscular disorders, advancing candidates from lead optimization through Phase I clinical testing.
Eligible applicants include nonprofit and for-profit organizations, small businesses, higher education institutions (public and private), state and local governments, tribal governments (federally and non-federally recognized), special district governments, and Indian housing authorities. The announcement also welcomes applications from Alaska Native and Native Hawaiian Serving Institutions, HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, AANAPISIs, faith-based and community-based organizations, U.S. territories and possessions, and non-domestic entities.
Awardee institutions retain assignment of intellectual property rights for biotherapeutic candidates developed under the program and gain assignment of IP rights from NIH contract research organizations (CROs) specializing in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. Applicants may collaborate with NIH-funded consultants and augment projects with these specialized CRO services.
The opportunity operates under multiple CFDA numbers reflecting participating NIH institutes: Mental Health Research Grants (93.242), Alcohol Research Programs (93.273), Drug Use and Addiction Research Programs (93.279), Environmental Health (93.113), Oral Diseases and Disorders Research (93.121), Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853), Research and Training in Complementary and Integrative Health (93.213), Aging Research (93.866), and Vision Research (93.867).
Synopsis
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Files
| File | Type | Posted |
|---|---|---|
| PAR-24-293-Full-Announcement.html | HTML file | |
| PKG00288386.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity